Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin, Michael; Chan, Joseph M; Tenet, Megan; Rizvi, Hira A; Shen, Ronglai; Riely, Gregory J; Rekhtman, Natasha; Daneshbod, Yahya; Quintanal-Villalonga, Alvaro; Penson, Alexander; Hellmann, Matthew D; Arcila, Maria E; Ladanyi, Marc; Pe'er, Dana; Kris, Mark G; Rudin, Charles M; Yu, Helena A

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin, Michael; Chan, Joseph M; Tenet, Megan; Rizvi, Hira A; Shen, Ronglai; Riely, Gregory J; Rekhtman, Natasha; Daneshbod, Yahya; Quintanal-Villalonga, Alvaro; Penson, Alexander; Hellmann, Matthew D; Arcila, Maria E; Ladanyi, Marc; Pe'er, Dana; Kris, Mark G; Rudin, Charles M; Yu, Helena A.

Afiliación

Offin M; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Chan JM; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Tenet M; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Rizvi HA; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Shen R; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Riely GJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Daneshbod Y; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Quintanal-Villalonga A; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Penson A; Program for Computational and System Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
Hellmann MD; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.
Arcila ME; Diagnostic Molecular Pathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ladanyi M; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Pe'er D; Program for Computational and System Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York.
Kris MG; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New Yor
Rudin CM; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New Yor
Yu HA; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: YuH@mskcc.org.

J Thorac Oncol ; 14(10): 1784-1793, 2019 10.

Article en En | MEDLINE | ID: mdl-31228622

Asunto(s)

Transformación Celular Neoplásica/patología; Mutación; Proteínas de Unión a Retinoblastoma/genética; Carcinoma Pulmonar de Células Pequeñas/mortalidad; Carcinoma Pulmonar de Células Pequeñas/patología; Proteína p53 Supresora de Tumor/genética; Ubiquitina-Proteína Ligasas/genética; Adenocarcinoma del Pulmón/tratamiento farmacológico; Adenocarcinoma del Pulmón/genética; Adenocarcinoma del Pulmón/mortalidad; Adenocarcinoma del Pulmón/patología; Adulto; Anciano; Anciano de 80 o más Años; Biomarcadores de Tumor/genética; Transformación Celular Neoplásica/efectos de los fármacos; Transformación Celular Neoplásica/genética; Receptores ErbB/genética; Femenino; Estudios de Seguimiento; Humanos; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/mortalidad; Neoplasias Pulmonares/patología; Masculino; Persona de Mediana Edad; Pronóstico; Inhibidores de Proteínas Quinasas; Factores de Riesgo; Carcinoma Pulmonar de Células Pequeñas/tratamiento farmacológico; Carcinoma Pulmonar de Células Pequeñas/genética; Tasa de Supervivencia

Palabras clave

EGFR-mutation; RB1; Small cell histologic transformation; TP53; Whole genome doubling

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Transformación Celular Neoplásica / Proteína p53 Supresora de Tumor / Ubiquitina-Proteína Ligasas / Carcinoma Pulmonar de Células Pequeñas / Proteínas de Unión a Retinoblastoma / Mutación Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Thorac Oncol Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google